Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease.
Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), which is the standard go-to drug for Alzheimer’s related dementia in up to 70 countries worldwide. Now they will collaborate with UK National Institute for Health Research (NIHR) endorsed teaching hospitals and the esteemed Institute for Neurology at UCL to concentrate on the effort to identify new gene targets for disorders of the central nervous system (CNS), of which there is a poorly understood cross-over.
Neurodegenerative disease (Parkinson’s, Huntington’s, ALS etc.) has experienced a massive boom in industry as of late, with a particular emphasis on Alzheimer’s, as we have been repeatedly stressing. Recent major developments include the development of a new phase III Tau-therapy for Alzheimer’s disease,